Overview
The goal of this observational study is to establish a digital diagnosis and treatment system for sarcopenia, integrating research outcomes into a unified approach encompassing a digital vaccine (early warning screening model), digital drug (intervention model associated with pathogenesis), and digital rehabilitation (preventive system combining early warning and treatment). This aims to create a digital visual tertiary prevention network for sarcopenia.
Research aims:
Evaluate the effectiveness of the digital vaccine through a cross-sectional epidemiological survey.
Establish a specialized cohort for sarcopenia through a longitudinal investigation, implementing the digital drug and digital rehabilitation interventions.
Participants will:
Engage in screening and assessment based on inclusion and exclusion criteria.
Be monitored longitudinally, with tailored interventions for those with muscle atrophy and regular follow-ups for at-risk individuals.
Key outcomes will focus on sarcopenia indicators, serum biomarkers, and clinical endpoints such as fracture rates, weakness classification, and quality of life.
Eligibility
Inclusion Criteria:
- Age ≥45 years;
- meeting sarcopenia diagnostic criteria;
- consent to participate in this study
Exclusion Criteria:
- Age <45 years;
- patients in acute phase of chronic illness;
- infectious disease patients;
- people who lack of independent mobility;
- people who lack of communication or cognitive skills;
- people who refusal to participate in this study